More than 10% of the world's population is chronically infected with HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV), all of which can cause severe disease and death. These viruses persist in part because continuous antigenic stimulation causes the deterioration of virus-specific cytotoxic T lymphocyte (CTL) function and survival. Additionally, antiviral CTLs autonomously suppress their responses to limit immunopathology by upregulating inhibitory receptors such as programmed cell death 1 (PD-1). Identification and blockade of the pathways that induce CTL dysfunction may facilitate the clearance of chronic viral infections. We found that the prostaglandin E2 (PGE 2 ) receptors EP2 and EP4 were upregulated on virus-specific CTLs during chronic lymphocytic choriomeningitis virus (LCMV) infection and suppressed CTL survival and function. We show that the combined blockade of PGE 2 and PD-1 signaling was therapeutic in terms of improving viral control and augmenting the numbers of functional virus-specific CTLs. Thus, PGE 2 inhibition is both an independent candidate therapeutic target and a promising adjunct therapy to PD-1 blockade for the treatment of HIV and other chronic viral infections. Fig. 1 ).
Therapeutic treatments to control or cure chronic viral infections such as HIV are in great need. Those capable of boosting the antigenspecific T cell response without excessive immunopathology would offer the most clinical promise. Many viruses that establish chronic infection have evolved strategies to evade immune detection. However, an equally important process is the host-driven immune suppression that attenuates antiviral immunity to limit immunopathology. This autoregulation is especially notable for activated CTLs, which by nature cause collateral damage [1] [2] [3] . Several negative CTL regulators have been identified in association with HCV, HBV and HIV infection in humans and lymphocytic choriomeningitis virus clone 13 (LCMV-CL13) infection in mice, including regulatory T cells (T reg cells), transforming growth factor β (TGF-β), interleukin 10 (IL-10), and the inhibitory receptors PD-1, TIM-3, CTLA-4 and LAG-3 (refs. [1] [2] [3] . Although the expression of inhibitory molecules is part of the normal autoregulatory machinery observed in all activated CTLs, over time the persistence of antigen and inhibitory receptor signaling can impair the proliferation, survival and effector function of CTLs (a process commonly referred to as exhaustion) or lead to physical depletion of certain epitopespecific CTL populations [1] [2] [3] . In these circumstances, the ability of CTLs to produce cytokines and kill infected targets is inversely proportional to viral load 4, 5 . Although CTL exhaustion contributes to viral persistence while limiting immunopathology during chronic infection, it also helps virus-specific CTLs persist by diminishing activation-induced T cell death [6] [7] [8] . Exhausted CTLs are also present in tumors [9] [10] [11] .
The blockade of inhibitory pathways such as the PD-1, IL-10 and TGF-β pathways can boost CTL numbers and effector functions in the face of chronic infection and cancer 7, [11] [12] [13] [14] [15] [16] [17] . The discovery of additional factors that govern CTL exhaustion might lead to more efficacious treatments. Here we identify an important role for PGE 2 in suppressing CTL survival and function during chronic LCMV infection. PGE 2 is a lipid synthesized from arachidonic acid by the sequential actions of cyclooxygenases (COX-1 and/or -2) and PGE synthases (PGESs). Microsomal PGES 1 (mPGES1), encoded by Ptges, is likely the most relevant PGES during inflammation and infection in mice and is also found in humans 18, 19 . PGE 2 has a paradoxical role in immune responses, acting as both a proinflammatory mediator 20 and a potent immunosuppressant, especially in tumors and type I immune responses to limit the functions of natural killer (NK) cells, CD4 and CTLs 19, 21, 22 . In tumors, PGE 2 induces IL-10, T reg cells and myeloid-derived suppressor cells 20, [23] [24] [25] . In CTLs, PGE 2 suppresses proliferation, cytotoxicity and IFNγ production in vitro 19 , and the use of COX-2 inhibitors to treat mice infected with murine leukemic retrovirus RadLV-Rs restored T cell proliferative responses 26 . In this study we found that the increased expression of the PGE 2 receptors EP2 (Ptger2) and EP4 (Ptger4) on virusspecific CTLs contributed to functional exhaustion and viral persistence in LCMV-CL13-infected mice, and that the PGE 2 signaling pathway is a promising target of therapeutic intervention, either on its own or with PD-1 blockade. PGE 2 directly suppresses effector functions of virus-specific CTLs PGE 2 can suppress the proliferation, cytotoxicity and cytokine production of activated CTLs in vitro [30] [31] [32] [33] . To determine its effects on CTLs in vivo during chronic viral infection, we generated Ptger2 −/− Ptger4 fl/fl Gzmb-Cre mice (hereinafter referred to as EP2/4-double knockout mice). In these animals, all cells lack EP2, but only cells that express granzyme B, such as virus-specific CTLs, will lack both EP2 and EP4. We then generated P14 + EP2/4-double knockout mice, which express the P14 T cell receptor (TCR) that recognizes the LCMV GP [33] [34] [35] [36] [37] [38] [39] [40] [41] peptide.
To examine the effects of PGE 2 on virus-specific CTL functions, we transferred P14 + CD8 + T cells from wild-type (WT) or EP2/4-double knockout mice into C57BL/6 mice that we subsequently infected with LCMV-CL13. Eight days later, we stimulated whole splenocytes from these mice with GP33 peptide in the presence or absence of PGE 2 and measured P14 + CTL cytokine production by intracellular cytokine staining (ICCS). We observed similar percentages of IFNγ-and TNF-α-producing cells among P14 + CD8 + T cells from WT and EP2/4-double knockout mice, but a greater proportion of cells from EP2/4-double knockout mice produced IL-2 ( Fig. 1c,d) . Importantly, the in vitro PGE 2 treatment of P14 + CTLs from WT mice suppressed the production of all three cytokines, with the greatest effects on TNF-α and IL-2 production (~75%-80% inhibition) (Fig. 1c,d ). In contrast, PGE 2 had very little effect on cytokine production by P14 + cells from EP2/4-double knockout mice, indicating that the deletion of EP2 and EP4 abolishes PGE 2 signaling in virus-specific CTLs (Fig. 1d) . Prior reports have suggested that PGE 2 can activate the tyrosine-protein kinase CSK and impair TCR activation 34, 35 . To better understand how [33] [34] [35] [36] [37] [38] [39] [40] [41] peptide stimulation with or without PGE 2 using phospho-flow cytometry. We found that PGE 2 signaling substantially reduced amounts of pERK and pS6, indicating that PGE 2 can impair both TCR signaling and cytokine production in virus-specific CTLs (Fig. 1e) .
PGE 2 suppresses numbers and function of virus-specific CTLs Next, we examined whether PGE 2 suppresses CTL responses during chronic LCMV-CL13 infection. For these studies we used EP2/4-double knockout mice and PGES-deficient mice (hereinafter referred to as mPGES1-knockout mice) to determine the systemic effects of reduced PGE 2 synthesis during LCMV-CL13 infection. We infected WT, EP2/4-double knockout and mPGES1-knockout mice with LCMV-CL13 and killed them at day 8 or 21 p.i. Using MHC class I tetramers to measure the frequency and numbers of LCMV-specific CTLs, we observed no significant increase in the virus-specific CTL populations in the EP2/4-double knockout and mPGES1-knockout mice relative to those in the WT controls at day 8 p.i. (Supplementary  Fig. 2a ). However, by day 21 p.i., there was a significant increase (approximately twofold) in the frequency and number of virus-specific CTLs in EP2/4-double knockout and mPGES1-knockout mice versus in the WT mice ( Fig. 2a,b) . The increased numbers of virus-specific CTLs in EP2/4-double knockout mice appeared specific to the dual deletion of both PGE 2 receptors on CTLs, as this was not observed in mice that contained only a germline PGE 2 receptor deficiency (i.e., EP2-knockout) ( Supplementary Fig. 3 ). We then measured the ability of virus-specific CTLs to produce cytokines in response to peptide stimulation and observed an increase in the percentage and number of cytokine-producing cells in the EP2/4-double knockout and mPGES1-knockout mice relative to those in the WT mice at day 21 p.i. (Fig. 2c,d and Supplementary Fig. 4 ).
The number of cells producing IFNγ and TNF-α increased approximately twofold to threefold, and the number of IL-2-producing cells was augmented even more (approximately fourfold to fivefold) in the animals with reduced PGE 2 signaling. These data demonstrated that PGE 2 signaling directly suppressed CTL cytokine production and contributed to the functional exhaustion of CTLs. However, despite the clear boost in the number and function of the antiviral CTLs, there was no significant improvement in viral control in the serum, spleen or liver with reductions in PGE 2 signaling alone (data not shown).
CTLs of EP2/4-double knockout mice express more PD-1 During LCMV-CL13 infection, several inhibitory receptors are upregulated on virus-specific CTLs to desensitize their TCRs to antigen 4 . Despite the increased numbers and cytokine production of virus-specific CTLs, we observed that the expression of PD-1 was increased in the CTLs of EP2/4-double knockout mice (Fig. 3) . A marginal, but insignificant, increase in PD-1 expression was also observed in the mPGES1-knockout mice. Furthermore, PD-1 was also expressed at higher levels on P14 + CTLs from EP2/4-double knockout mice versus those from Fig. 5 ), indicating CTL-autonomous upregulation of PD-1. Given that PGE 2 can suppress TCR signaling (Fig. 1e) and that TCR signaling is a potent inducer of PD-1 expression 36 , it is possible that TCR signaling is more robust in CTLs lacking PGE 2 signaling and that this further upregulates their PD-1 expression.
Co-blockade of PGE 2 and PD-1 boosts CTL responses Recent studies have shown that the combined blockade of two or more inhibitory pathways can have additive effects in improving CTL responses during LCMV-CL13 infection 28, 37 . For this reason, and because PD-1 was increased on CTLs from EP2/4-double knockout mice, we tested the effects of the simultaneous blockade of PD-1 and PGE 2 on CTL responses and viral control. Following a protocol similar to that used previously 7 , we depleted WT, EP2/4-double knockout and mPGES1-knockout mice of CD4 + T cells using GK1. Data were statistically analyzed using ANOVA. (g) Spleen and serum were harvested from mice infected with LCMV-CL13 at day 42 p.i. Scatter plots show viral titers in serum and spleen measured by plaque assay. Dashed horizontal line indicates the limit of detection of the assay (50 PFU ml −1 for serum assay). Data were compiled from two independent experiments with a total of seven vehicle-treated WT, five vehicle-treated mPGES1-knockout, seven anti-PD-L1-treated WT and six anti-PD-L1-treated mPGES1-knockout mice and were statistically analyzed using ANOVA. Error bars represent s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001. npg persistent high-titer viremia, rapid depletion of NP396-specific CTLs and profound functional exhaustion 38 . Prior work has shown that the blockade of PD-1-PD-L1 signaling in this system enhances the number and function of CTLs and reduces viral titers 7 .
In the CD4-depleted ('helpless') system, the deletion of EP2 and EP4 had little effect on the LCMV-specific CTL population (Fig. 4b) . However, the systemic reduction of PGE 2 in the mPGES1-knockout mice led to an increase (approximately twofold) in the number of virus-specific CTLs versus that in WT mice (Fig. 4c) . As expected, anti-PD-L1 treatment in WT mice caused an increase in the numbers of LCMV-specific CTLs compared to those in vehicle-treated WT controls (Fig. 4a-c) . Specifically, anti-PD-L1 blockade in WT mice caused the expansion of populations of GP276-and GP33-specific CTLs and, to a lesser extent, NP396-specific CTLs (Fig. 4a-c) . PD-L1 blockade increased the number of IFNγ-and TNF-α-producing CTLs, but it did not affect IL-2 production (Fig. 4d-f) .
The effects of anti-PD-L1 blockade were substantially enhanced in mice deficient in PGE 2 signaling. Notably, there was a particularly strong boost (approximately fivefold or more) in the frequency and numbers of NP396-specific CTLs in EP2/4-double knockout and mPGES1-knockout mice treated with anti-PD-L1 versus those in their WT counterparts (Fig. 4a-c) . Blockade of PD-L1 in the EP2/4-double knockout mice also increased the numbers of GP34-specific CTLs (Supplementary Fig. 6 ), another immunodominant virus-specific CTL population normally deleted during LCMV-CL13 infection 39 . Thus, blockade of PGE 2 signaling complemented the effects of anti-PD-L1 therapy and helped restore immunodominant CTLs typically deleted during chronic LCMV-CL13 infection.
We next examined the effects of blocked PD-L1 and PGE 2 signaling on cytokine production by antiviral CTLs. PD-L1 blockade alone potently boosted the frequency and number of IFNγ-and TNF-α-producing cells (Fig. 4d-f) , but a more profound effect was observed on the NP396-specific CTL population when both PD-1 and PGE 2 signaling were reduced concomitantly. Notably, we observed fourfold more IL-2-producing CTLs in EP2/4-double knockout and mPGES1-knockout mice treated with anti-PD-L1 than in WT mice treated with anti-PD-L1 (Fig. 4d-f) . Moreover, we found 12-15-fold more NP396-specific IL-2-producing CTLs in anti-PD-L1-treated EP2/4-double knockout and mPGES1-knockout mice than in anti-PD-L1-treated WT mice, which showed that reducing PGE 2 signaling increased the functionality of the CTLs in addition to their numbers (Fig. 4d-f ).
Co-blockade of PD-L1 and PGE 2 enhances viral control
To determine whether the combined effects of reduced PD-1-PD-L1 and PGE 2 signaling enhanced viral clearance in the (CD4-depleted) 'helpless' system, we measured viral titers in the serum and spleen at day 42 p.i. We observed significant reductions in the viral titers in the spleens of mPGES1-knockout mice compared to those of their WT counterparts, indicating that systemic reduction of PGE 2 alone enhanced viral control (Fig. 4g) . However, there was no significant difference between the WT and the EP2/4-double knockout mice (data not shown). As previously reported 7 , blockade of PD-L1 alone enhanced viral clearance in the serum and spleen. Notably, the blockade of PD-L1 in mPGES1-knockout mice further enhanced viral control. Compared to those in WT (vehicle-treated) controls, viral titers decreased by as much as 10-100-fold, depending on the tissue examined, when we reduced PGE 2 and PD-1 signaling simultaneously (Fig. 4g) .
Pharmacologic inhibition of PGE 2 production with PD-L1 blockade PGE 2 production can be dramatically attenuated via pharmacologic inhibition of COX-2, a key enzyme responsible for the synthesis of PGE 2 during immune responses. We tested whether daily oral administration of celecoxib (100 mg per kilogram of chow) could npg boost antiviral CTL responses. Mice were depleted of CD4 + T cells, infected with LCMV-CL13 and fed celecoxib or control diet. Then, beginning on day 28 p.i., we treated mice with either mAb to PD-L1 or PBS for 2 weeks. Mice treated with celecoxib alone showed no difference in virusspecific CTL percentages, numbers or cytokine production relative to untreated mice (Fig. 5) . Moreover, mice treated with anti-PD-L1 or those cotreated with celecoxib and anti-PD-L1 had similar increases in the total numbers of virus-specific CTLs. However, inhibition of both PGE 2 and PD-L1 signaling boosted the percentages of NP396-specific CTLs by threefold to fourfold compared to those in mice treated with anti-PD-L1 alone (Fig. 5) , mirroring the effects seen in the genetic models (Fig. 4) . Co-treatment with celecoxib and anti-PD-L1 increased the number of cytokine-producing NP396-specific CTLs more than treatment with anti-PD-L1 alone did, and as observed in the genetic models, there was a significant elevation in the numbers of IL-2-producing CTLs (a 4.2-fold increase in the cotreated mice versus in those treated with anti-PD-L1 alone). However, this augmentation of T cell function in the cotreated mice was insufficient to lower viral titers below the values seen with anti-PD-L1 treatment alone (data not shown). Nonetheless, these results provide additional evidence that pharmacological disruption of PGE 2 signaling could serve as an adjunct to PD-L1 blockade for boosting the responses of protective, immunodominant CTL populations during chronic antigen exposure.
PGE 2 promotes Bim expression in exhausted CTLs
We investigated whether the increased number of NP396-specific CTLs in the anti-PD-L1-treated EP2/4-double knockout mice was due to enhanced cell division or survival. For measurement of T cell proliferation, WT or EP2/4-double knockout mice (depleted of CD4 + T cells), treated with or without anti-PD-L1, received BrdU in their drinking water during the second week of anti-PD-L1 treatment. The NP396-specific CTLs divided at similar rates in the vehicle-treated WT and EP2/4-double knockout mice (~40%-50% of the cells incorporated BrdU), indicating that reduced PGE 2 signaling had little effect on CTL division (Fig. 6a) . The rates of cell division increased greatly when PD-1-PD-L1 signaling was blocked (>90% of the cells incorporated BrdU). However, there was no additive effect of blocking PGE 2 and PD-1 signaling simultaneously (Fig. 6a) . These data suggested that PGE 2 signaling was not suppressing division of the virus-specific CTLs during chronic viral infection. Next, we analyzed the frequency of CTLs undergoing apoptosis by staining the cells for the proapoptotic molecules Bim 40 and active caspase-3 (using CaspGLOW reagents) 41 . On the basis of these markers, NP396-specific CTLs in EP2/4-double knockout mice exhibited significantly lower rates of apoptosis than their WT counterparts (Fig. 6b,c) . The frequency of CaspGLOW positivity and the amounts of Bim within the NP396-specific CTLs in the EP2/4-double knockout mice were approximately half those of the WT controls (Fig. 6b,c) . A similar reduction in the number of proapoptotic NP396-specific CTLs was observed in mice treated with anti-PD-L1, and this effect was enhanced incrementally when PGE 2 and PD-1 signaling were blocked simultaneously (Fig. 6b,c) . Blocking PGE 2 also led to a significant reduction in CaspGLOW positivity in GP33-specific CTLs, Fig. 7 ). Blocking PGE 2 had no effect on CaspGLOW positivity in GP276-specific CTLs (Supplementary Fig. 7) . Thus, PGE 2 appears to play a more dominant role in suppressing CTL survival than cell division. These findings indicate that when PGE 2 and PD-1 signaling were reduced simultaneously, the combination of decreased CTL death and increased cell division effectively restored the immunodominant NP396-specific CTL population and restrained viral load.
DISCUSSION
A new way to control or cure chronic viral infections is to augment the numbers and action of virus-specific CTLs via the blockade of inhibitory signaling pathways. Here we demonstrate that PGE 2 impaired CTL survival and effector functions during chronic LCMV infection. Blockade of PGE 2 signaling either directly on the CTLs (via EP2 and EP4 deletion) or systemically (via mPGES1 deletion or through celecoxib treatment) increased antigen-specific CTL numbers and cytokine production, especially IL-2 production. The reduction of PGE 2 in mice lacking mPGES1 also led to improved viral control when CD4 + T cell help was absent, a situation typically associated with persistent viremia and marked CTL exhaustion. It is likely that the enhanced viral control observed in the absence of CD4 + T cell help in mPGES1-knockout mice, but not in EP2/4-double knockout mice, resulted in part from the effects of PGE 2 on cell types other than CTLs 19, 20 . Similarly, the finding that EP2/4-double knockout mice exhibited a greater increase in viral-specific CTL numbers in CD4-replete versus CD4-depleted environments might indicate that PGE 2 signaling also suppresses antiviral CD4 + T cell responses. Thus, systemic blockade of PGE 2 signaling, as opposed to focused targeting to CTLs, may be of greater therapeutic benefit for boosting T cell responses. Importantly, we found that simultaneous inhibition of PGE 2 and PD-1 signaling during LCMV-CL13 infection had additive effects in boosting the numbers, function and viral control of CTLs, in part by restoring the immunodominant populations of virus-specific CTLs that are typically deleted. Furthermore, the administration of celecoxib with anti-PD-L1 boosted NP396-specific CTL responses and IL-2 production, consistent with the phenotype observed in the genetically mutated mice. This provides a rationale for combining nonsteroidal anti-inflammatory drug (NSAID) treatment with PD-1-PD-L1 blockade in patients undergoing immunotherapy for cancer or viral infection.
Although few studies directly address the effects of blocked PGE 2 signaling on dysfunctional CTLs, indirect evidence indicates that therapeutic PGE 2 blockade may boost CTL function. For example, T cells from HIV-infected individuals have greater amounts of cAMP, and protein kinase A (PKA) type I antagonists can augment T cell proliferation and IL-2 production 42, 43 . Moreover, treatment of HIV-infected individuals with COX-2 inhibitors increased perforin and IFNγ expression and proliferative responses in T cells 32, 44, 45 . The smaller effect size in the celecoxib experiments versus in the genetic models might be simply a result of suboptimal celecoxib dosing, or, alternatively, it is possible that other prostanoids downstream of COX-2 play beneficial roles in antiviral immunity. In any case, the results of the pharmacologic co-treatment studies underscore the potential therapeutic implications of our findings, and because NSAIDs have been used worldwide for decades, inhibition of PGE 2 signaling is likely to be a safe and affordable adjunctive therapy to PD-1-PD-L1 blockade. Furthermore, several studies have shown that people who take aspirin, and in some cases NSAIDs, on a regular basis have a lower risk of developing multiple types of cancer 46, 47 . It will be of interest to further explore therapeutic possibilities for the enhancement of CTL function using COX-2 blockade, with or without blockade of the PD-1 pathway, in patients with chronic infection or cancer. PGE 2 may impair CTL survival in part by increasing the expression of Bim, which is responsible for the deletion of virus-specific CTLs during chronic infection 48, 49 . However, it is unclear which factors induce Bim in antigen-specific CTLs during chronic viral infection. Our data indicate that PGE 2 might be one such factor. PGE 2 -induced cAMP may increase Bim levels in CTLs, as increased cAMP and PKA activity stabilizes Bim EL and induces apoptosis in thymocytes and lymphoma cell lines [50] [51] [52] [53] . IL-2 is necessary for the maintenance of virus-specific CTLs during chronic LCMV infection [54] [55] [56] , and PGE 2 -mediated repression of IL-2 production may lead to CTL apoptosis, particularly in NP396-specific T cells. Given that PGE 2 -induced cAMP has been shown to increase CSK activation and inhibit TCR signaling 34, 35 , altered TCR signaling might account for our observed changes in IL-2 expression.
Reversal of T cell dysfunction is a new and promising approach for treating both chronic viral infection and cancer. Here we have shown that the lipid PGE 2 suppresses exhausted antigen-specific CTL function and promotes CTL apoptosis. Additionally, we discovered that combined blockade of PGE 2 and PD-1 is therapeutically superior to blockade of either one alone in controlling chronic viral infection. Co-modulation of PGE 2 and PD-1 signaling may represent a potent therapeutic avenue for the treatment of certain chronic diseases.
METHODS
Methods and any associated references are available in the online version of the paper. 
